Manufacturer: Sun PharmaceuticalsPack: 0.5mg 4 pillsChemical Substance: Cabergoline (Cabaser)
Dostinex® is a dopaminergic derivative of ergoline and is characterized by a prolactin-lowering effect due to direct stimulation of the D2-dopamine receptors of lactotrophic pituitary cells. In addition, when taking higher doses compared to those for lowering serum prolactin levels, Dostinex® has a central dopaminergic effect due to stimulation of D2 receptors.
Reduction in the concentration of prolactin in the blood plasma is observed within 3 hours after taking the drug and persists for 7-28 days in healthy volunteers and patients with hyperprolactinaemia, and up to 14-21 days – in women in the postpartum period.
Dostinex ® has a strictly selective effect, does not affect the basal secretion of other hormones of the pituitary and cortisol. Prolactin-lowering effect of the drug is dose-dependent both in terms of severity and duration of action.
To the pharmacodynamic effects of Dostinex®, not related to the therapeutic effect, only the reduction in blood pressure (BP) refers. With a single dose of the drug, the maximum hypotensive effect is noted during the first 6 hours and is dose-dependent.
Inhibition or suppression of physiological lactation
Preventing physiological postpartum lactation immediately after birth or for suppressing existing lactation in such cases: after delivery, if the mother decided not to breast-feed the baby or when breastfeeding is contraindicated to the mother or child for medical reasons; After the birth of a dead fetus or after an abortion.
Treatment of hyperprolactinemia
Violations associated with hyperprolactinemia, including amenorrhea, oligomenorrhoea, anovulation and galactorrhea. Treatment of patients with prolactin-secreting adenomas of the pituitary gland (micro- and macro-prolactinomas), idiopathic hyperprolactinaemia or empty Turkish saddle syndrome with associated hyperprolactinemia, which are the main pathological conditions that cause the abovementioned clinical manifestations.
Dosing and Administration
Inside, with food.
Prevention of lactation: 1 mg once (2 tablets of 0.5 mg), on the first day after childbirth.
Suppression of steady lactation: 0.25 mg (1/2 tablet) twice a day every 12 hours for two days (total dose is 1 mg). In order to reduce the risk of orthostatic hypotension in breast-feeding mothers, a single dose of Dostinex® should not exceed 0.25 mg.
Treatment of violations associated with hyperprolactinemia: the recommended initial dose is 0.5 mg per week in a single dose (1 tablet 0.5 mg) or in two divided doses (1/2 tablet 0.5 mg, for example, on Monday and Thursday) . The increase in the weekly dose should be carried out gradually – by 0.5 mg with a monthly interval until the optimal therapeutic effect is achieved. The therapeutic dose is usually 1 mg per week, but can range from 0.25 to 2 mg per week. The maximum dose for patients with hyperprolactinemia should not exceed 4.5 mg per week.
Moderately expressed, appear within the first 2 weeks and pass independently.
From the nervous system: dizziness, headache, insomnia; With prolonged use – weakness, drowsiness, depression, asthenia; Rarely – paresthesia, syncope.
From the digestive system: nausea, dry mouth, epigastric pain, abdominal pain; With prolonged use – vomiting, constipation, gastritis.
On the part of the CAS: a decrease in blood pressure, palpitations; Rarely – orthostatic hypotension.
Other: mastodinia, lowering of Hb level after recovery of menstruation, epistaxis, “tides” of blood to the skin of the face, transient hemianopia, twitching of leg muscles, allergic skin reactions to components of Dostinex.